sperogenix
Sperogenix is a privately held Chinese biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing, operating a platform-based R&D and commercialization business focused on therapies for rare diseases.
- Company typePrivate
- Founded2019
- HeadquartersChaoyang, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What sperogenix does
Sperogenix is a privately held, China-based biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing. According to firmographic data, the company operates a platform-based business model dedicated to the research and development and commercialization of rare disease therapeutics — a therapeutic category characterized by small patient populations, complex clinical development, and post-approval regulatory exclusivity. Sperogenix has a workforce of 51-100 employees and maintains a Chinese operating geography, with a public website at sperogenix.com that, at the time of data capture, displays only a default nginx placeholder page rather than active corporate content.
From a business-model perspective, Sperogenix follows the standard specialty-pharma trajectory: a pre-commercial or early-clinical R&D operation that intends to generate future revenue through proprietary drug commercialization and, in some cases, licensing or partnership income. The available data does not document specific drug candidates, therapeutic-area focus, pipeline depth, partnerships, pricing models, customer segments, or commercialization milestones, and the company has no disclosed public ticker, parent company, or detailed ownership structure.
The absence of recorded patents, trademarks, certifications, regulatory actions, M&A activity, leadership team bios, or strategic partnerships materially constrains visibility into the company's operational specifics. The only verifiable recent strategic event is a second funding round recorded on 2025-06-06 with undisclosed amount and undisclosed investors. As a result, while Sperogenix's category positioning (rare disease drug developer in China) is clear, the underlying technology architecture, competitive position, and go-to-market mechanics cannot be substantively characterized from the supplied inputs.
sperogenix firmographics
Firmographics- Name
- sperogenix
- Website
- https://sperogenix.com
- Company type
- Private
- Founded year
- 2019
- Headcount range
- 51–100 employees
- Short description
- Sperogenix is a privately held Chinese biopharmaceutical company founded in 2019 and headquartered in Chaoyang, Beijing, operating a platform-based R&D and commercialization business focused on therapies for rare diseases.
- Ownership category
- akta.pro rank
sperogenix industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
- akta.pro secondary industry
- Rare Gastroenterology & Hepatology Disorder Therapies (HLAIAIAL)
Keywords
Where sperogenix is headquartered
LocationHeadquarters
- HQ city
- Chaoyang
- HQ country
- China
- HQ region
- Asia
Markets served
sperogenix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
sperogenix product offering
Product offeringCore offering
Sperogenix is a platform-based biopharmaceutical company that conducts the research, development, and commercialization of therapies for rare diseases. The company integrates drug discovery and development activity with commercialization to bring rare disease treatments to market.
Differentiator
Problem solved
Functional benefit
Companies that use sperogenix
Customer profileIdeal customer profiles1 record
sperogenix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
sperogenix partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights3 records
sperogenix competitors and assessment
Company assessmentBroad incumbents
- Ultragenyx Pharmaceutical: Commercial-stage rare disease company developing therapies for rare and ultra-rare genetic diseases, providing a relevant comparator for platform economics, pipeline diversification, and commercialization strategy in rare disease.
- BioMarin Pharmaceutical: Established global rare disease company specializing in treatments for serious and life-threatening rare genetic conditions; serves as the global benchmark for the rare disease commercial model that Sperogenix is attempting to replicate in China.
- Sanofi (Genzyme) - Rare Disease: Global pharmaceutical major with one of the largest rare disease franchises through Genzyme, covering lysosomal storage disorders and other rare conditions; representative of the dominant incumbent rare disease commercial model.
- Takeda Pharmaceutical (Rare Disease): Global pharmaceutical company with a substantial rare disease and plasma-derived therapies franchise following the Shire acquisition; relevant as a large incumbent with established rare disease commercial infrastructure.
Regional players
- Genor Biopharma: China-based biopharmaceutical company focused on oncology and autoimmune diseases; comparable as a similarly-sized, China-domiciled clinical-stage biopharma facing the same regulatory and capital access dynamics.
- I-Mab Biopharma: China-based clinical-stage biopharmaceutical company developing innovative biologics; comparable as a similarly-sized Chinese biotech navigating capital markets and regulatory pathways in the same regional environment.
Direct peers
- LianBio: China-focused clinical-stage biopharmaceutical company partnering with global innovators to bring therapies to Chinese patients, including rare and serious disease assets with a comparable cross-border licensing model.
- Everest Medicines: China-based clinical-stage biopharmaceutical company focused on licensing and developing innovative therapies, with a significant emphasis on rare disease and specialty indications in the Greater China region.
- CANBridge Pharmaceuticals: China-focused rare disease company developing and commercializing therapies for rare and orphan indications, with a comparable platform-style approach and similar geographic focus on serving Chinese patients with rare conditions.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
sperogenix financial estimates
Financial estimateRevenue estimate
Valuation estimate
sperogenix leadership team
Management profileNumber of profiles
sperogenix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
sperogenix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about sperogenix
What does sperogenix do?
Sperogenix is a platform-based biopharmaceutical company that conducts the research, development, and commercialization of therapies for rare diseases. The company integrates drug discovery and development activity with commercialization to bring rare disease treatments to market.
When was sperogenix founded?
sperogenix was founded in 2019. It employs 51 to 100 people.
Where is sperogenix based?
sperogenix is headquartered in Chaoyang, China, in the Asia region.
Who are sperogenix's main competitors?
Broad incumbents on record are Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, Sanofi (Genzyme) - Rare Disease and Takeda Pharmaceutical (Rare Disease). Regional players are Genor Biopharma and I-Mab Biopharma. Direct peers are LianBio, Everest Medicines and CANBridge Pharmaceuticals.
Does sperogenix have an API?
No public API is recorded for sperogenix.
What industry is sperogenix in?
sperogenix's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies, with a secondary code of HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.